Record Details

Immune dysregulation in myelodysplastic syndrome

Hematology Reports

View Archive Info
Field Value
Authentication Code dc
Title Statement Immune dysregulation in myelodysplastic syndrome
Added Entry - Uncontrolled Name Chiharu Sugimori; H. Lee Moffitt Cancer Center
Alan F. List; H. Lee Moffitt Cancer Center
Pearlie K. Epling-Burnette; H. Lee Moffitt Cancer Center
NCI-CA11211201; NCI-CA129952-01
Uncontrolled Index Term Medicine; Hematology; Myelodysplastic Syndrome
Myelodysplastic Syndrome, autoimmunity, T lymphocytes, treatment
Summary, etc. Myelodysplastic syndrome (MDS) represents one of the most challenging health-related problems in the elderly. Characterized by dysplastic morphology in the bone marrow in association with ineffective hematopoiesis, pathophysiological causes of this disease are diverse including genetic abnormalities within myeloid progenitors, altered epigenetics, and changes in the bone marrow microenvironment. The concept that T-cell mediated autoimmunity contributes to bone marrow failure has been widely accepted due to hematologic improvement after immunosuppressive therapy (IST) in a subset of patients. Currently, IST for MDS primarily involves anti-thymocyte globulin (ATG)-based regimens in which responsiveness is strongly associated with younger (under 60 years) age at disease onset. In such cases, progressive cytopenia may occur as a consequence of expanded self-reactive CD8+ cytotoxic T lymphocytes (CTLs) that suppress hematopoietic progenitors. Although most hematologists agree that IST can offer durable hematologic remission in younger patients with MDS, an international clinical study and a better understanding of the molecular mechanisms contributing to the expansion of self-reactive CTLs is crucial. In this review, data accumulated in the US, Europe, and Asia will be summarized to provide insight and direction for a multi-center international trial.
Publication, Distribution, Etc. PAGEPress Publications
Electronic Location and Access application/pdf
Data Source Entry Hematology Reports; Vol 2, No 1 (2010); e1
Language Note en
Terms Governing Use and Reproduction Note <p>PAGEPress has chosen to apply the <a href="" target="_blank">Creative Commons Attribution License</a> (CCAL) to all manuscripts to be published. </p> <p>An Open Access Publication is one that meets the following two conditions:</p> <ol><li>The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li><li>A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li></ol> Authors who publish with this journal agree to the following terms: 1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. 3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).